A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study

Diana F. Nelson, Marie Diener-West, Alan S. Weinstein, David Schoenfeld, James S. Nelson, William T. Sause, Chu Huai Chang, Robert Goodman, Steven Carabell

Research output: Contribution to journalArticlepeer-review

Abstract

This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.

Original languageEnglish (US)
Pages (from-to)1793-1800
Number of pages8
JournalInternational journal of radiation oncology, biology, physics
Volume12
Issue number10
DOIs
StatePublished - Oct 1986
Externally publishedYes

Keywords

  • BCNU
  • Malignant glioma
  • Misonidazole
  • Radiation sensitizers
  • Radiation therapy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study'. Together they form a unique fingerprint.

Cite this